Bladder Cancer
Bladder cancer is one of the few cancers where the first sign — blood in the urine — is usually unmistakable. Acting promptly on that sign, with a quick cystoscopy, often means catching the disease at a stage when it can be managed without ever removing the bladder.
What bladder cancer is — in plain words
The bladder is a hollow muscular bag that stores urine. Bladder cancer almost always begins in the cells lining the inside of the bladder (urothelial cells). The major risk factors are smoking (by far the most important), exposure to industrial dyes and chemicals, chronic bladder irritation or infection, and prior pelvic radiation.
The most important early distinction is between cancers that have not invaded the muscle of the bladder wall (non-muscle-invasive bladder cancer, NMIBC — about 75% of new cases) and those that have (muscle-invasive bladder cancer, MIBC). The two are managed quite differently.
Signs and symptoms to take seriously
Blood in the urine
Visible (pink, red or brown urine) or invisible (picked up on a urine test). Even a single episode without infection deserves investigation.
Frequent or urgent urination
New, persistent need to pass urine more often or more urgently, without an infection to explain it.
Pain or burning on urination
Persistent symptoms that don't respond to antibiotics for a suspected infection.
Pelvic or back pain
Less common, often a sign of more advanced disease.
"Blood in the urine is never normal. It's not 'just dehydration' or 'just the heat.' Every adult with visible blood in the urine — even once, even briefly — needs a cystoscopy. It might save the bladder, and it might save the life."
How bladder cancer is diagnosed
- Urine tests — to look for blood, infection, and cancer cells (urine cytology).
- Cystoscopy — a thin camera passed through the urethra to look directly inside the bladder. This is the definitive test.
- CT urogram — a contrast-enhanced CT scan that images the kidneys, ureters and bladder.
- Transurethral resection (TURBT) — both the diagnostic procedure and, for non-muscle-invasive disease, the first treatment. The tumour is removed through the cystoscope, and the depth of invasion assessed.
- Staging scans — for muscle-invasive disease, CT of the chest, abdomen and pelvis, sometimes PET-CT and a bone scan.
Stages — what the numbers mean
Stage 0 / I (NMIBC)
Cancer confined to the inner lining or just below it. Managed with cystoscopic resection (TURBT) plus intravesical therapy. Bladder preserved.
Stage II–III (MIBC)
Cancer has grown into the bladder muscle or beyond. Treated with either radical cystectomy (with chemotherapy first) or bladder-preserving trimodal therapy.
Stage IV (locally advanced or metastatic)
Spread to nearby organs, distant lymph nodes or distant organs. Treated with systemic chemotherapy, immunotherapy and targeted therapy.
Carcinoma in situ (CIS)
A flat, high-grade lesion. Despite being non-invasive, it is aggressive and needs intensive intravesical BCG therapy and close surveillance.
How we treat non-muscle-invasive bladder cancer
Transurethral resection of bladder tumour (TURBT)
The tumour is removed through a cystoscope under anaesthesia. A second TURBT a few weeks later is often advised to confirm complete removal and check for any missed disease.
Intravesical therapy
- Intravesical BCG — a weakened tuberculosis vaccine instilled into the bladder weekly for six weeks, then maintenance for 1–3 years. The single most effective treatment for high-risk non-muscle-invasive disease, and one of the earliest forms of cancer immunotherapy.
- Intravesical mitomycin or gemcitabine — chemotherapy instilled into the bladder, used for lower-risk disease or after TURBT.
Surveillance cystoscopy
Regular cystoscopy every 3–6 months in the first years, then less frequently — because non-muscle-invasive bladder cancer often recurs and surveillance catches it early.
How we treat muscle-invasive bladder cancer
Neoadjuvant chemotherapy
Cisplatin-based combination chemotherapy (most often dose-dense MVAC or gemcitabine-cisplatin) given before surgery, which improves cure rates substantially. This step is essential whenever the patient's kidney function and fitness allow. Read more about chemotherapy →
Radical cystectomy
Removal of the entire bladder and the nearby lymph nodes, with creation of a new way to pass urine — either an ileal conduit (a stoma on the abdomen) or a neobladder (a new bladder fashioned from a piece of intestine that lets the patient pass urine more naturally). Recovery is significant; modern enhanced-recovery protocols speed it up.
Trimodal therapy (bladder preservation)
For selected patients — particularly those with a single tumour, no carcinoma in situ, and good baseline bladder function — combined maximal TURBT, chemotherapy and radiation can achieve cure rates comparable to cystectomy while preserving the bladder. The choice between cystectomy and trimodal therapy is individualised.
Adjuvant immunotherapy
Nivolumab given for up to a year after cystectomy improves outcomes in patients with high-risk pathology, and is now standard.
How we treat advanced bladder cancer
First-line systemic therapy
The current standard is enfortumab vedotin (an antibody-drug conjugate targeting Nectin-4) combined with pembrolizumab — a regimen that has substantially improved survival over older chemotherapy approaches. Platinum-based chemotherapy combinations remain important alternatives.
Immunotherapy
Checkpoint inhibitors (pembrolizumab, nivolumab, avelumab, atezolizumab) are central to modern bladder cancer treatment, either alone, in combination, or as maintenance after chemotherapy. Read more about immunotherapy →
Targeted therapy
FGFR3 mutations (present in about 15% of advanced cases) are targeted by erdafitinib, a daily tablet that produces meaningful responses in selected patients.
What the outlook honestly looks like
For non-muscle-invasive bladder cancer treated with TURBT and BCG, long-term outcomes are excellent — many patients live a normal lifespan with the bladder preserved, requiring only ongoing surveillance. For muscle-invasive disease treated with neoadjuvant chemotherapy and cystectomy, five-year survival is around 50–60%. For metastatic disease, the addition of enfortumab vedotin and pembrolizumab to first-line treatment has roughly doubled median survival compared with chemotherapy alone — a major recent advance.
Prevention and early detection
- Stop smoking — the single most important risk factor.
- Limit chemical exposure — workers in dye, rubber, leather and chemical industries should use proper protective equipment.
- Drink adequate fluids — reduces concentration of carcinogens in urine.
- Investigate blood in the urine promptly — the single most important behaviour for early diagnosis.
Life during treatment
BCG instillations cause some bladder irritation for a day or two after each treatment — generally well tolerated. After cystectomy with a neobladder or ileal conduit, life adjusts. Stoma nurses spend whatever time is needed to make daily care confident and routine. Many cystectomy patients return to swimming, travel, exercise and intimacy within months. Sexual function after cystectomy can be affected; modern nerve-sparing techniques and frank conversations about expectations help.
After treatment — survivorship
For non-muscle-invasive disease, regular cystoscopy and urine cytology continue for years. For cystectomy patients, surveillance imaging, attention to kidney function, vitamin B12 levels (after ileal conduit), and stoma care are all part of long-term follow-up. Read about survivorship care →
Found blood in the urine? Or recently diagnosed with bladder cancer?
Bring the cystoscopy and TURBT report, the pathology and any scans. We will explain whether the disease is non-muscle-invasive or muscle-invasive — that distinction shapes everything that follows — and lay out the options.
Medically reviewed by
Dr. Rehan Abdullah
Dr. Rehan Abdullah is a dual-trained clinical and radiation oncologist with over a decade of experience treating both solid tumours and hematologic malignancies. He serves as Consultant Oncologist at INMOL Hospital and sees patients at Farooq Hospital and Healthnox Medical Center, Lahore. Read full profile →
This page is patient education, not a substitute for an in-person consultation. Cancer care must be individualised. Read our medical disclaimer →